Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254 , April 2005

Influence of psychotherapy attendance on buprenorphine treatment outcome

  • Iván D. Montoya, M.D., M.P.H.

      Affiliations

    • Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Rockville, MD 20892, USA
    • Corresponding Author InformationCorresponding author. Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, 6001 Executive Blvd. Bethesda, MD 20892-9551, USA. Tel.: +1-301-443-8639; fax: +1-301-443-2599.
    • ,
  • Jennifer R. Schroeder, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Kenzie L. Preston, Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Lino Covi, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Annie Umbricht, M.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Carlo Contoreggi, M.D.

      Affiliations

    • Brain Imaging Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA
    • ,
  • Paul J. Fudala, Ph.D.

      Affiliations

    • University of Pennsylvania School of Medicine and the Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Rolley E. Johnson, Pharm.D.

      Affiliations

    • Reckitt Benckiser Pharmaceuticals, Inc. and Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    • ,
  • David A. Gorelick, M.D., Ph.D.

      Affiliations

    • Clinical Pharmacology & Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health & Human Services, Baltimore, MD 21224, USA

Received 22 August 2004 ,Revised 22 August 2004 ,Accepted 11 January 2005.

References 

  1. Barber JP, Crits-Christoph P, Luborsky L. Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. Journal of Consulting and Clinical Psychology. 1996;64:619–622
  2. Barber JP, Foltz C, Crits-Christoph P, Chittams J. Therapists' adherence and competence and treatment discrimination in the NIDA Collaborative Cocaine Treatment Study. Journal of Consulting and Clinical Psychology. 2004;60:29–41
  3. Barber JP, Luborsky L, Gallop R, Crits-Christoph P, Frank A, Weiss RD, et al. Therapeutic alliance as a predictor of outcome and retention in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Journal of Consulting and Clinical Psychology. 2001;69:119–124
  4. Barrowclough C, Tarrier N, Lewis S, Sellwood W, Mainwaring J, Quinn J, et al. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. British Journal of Psychiatry. 1999;174:505–511
  5. Batki SL, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. Journal of Clinical Psychopharmacology. 1993;13:243–250
  6. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology. 1997;65:803–810
  7. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Archives of General Psychiatry. 1994;51:989–997
  8. Colom F. The mechanism of action of psychotherapy. Bipolar Disorders. 2002;4(Suppl. 1):102
  9. Colom F, Vieta E, Martinez A, Jorquera A, Gasto C. What is the role of psychotherapy in the treatment of bipolar disorder?. Psychotherapy and Psychosomatics. 1998;67:3–9
  10. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry. 2003;60:402–407
  11. Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, et al. Psychoeducation efficacy in bipolar disorders: Beyond compliance enhancement. Journal of Clinical Psychiatry. 2003;64:1101–1105
  12. Covi L, Hess JM, Kreiter NA, Haertzen CA. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. American Journal of Drug and Alcohol Abuse. 1995;21:327–344
  13. Covi L, Hess JM, Schroeder JR, Preston KL. A dose response study of cognitive behavioral therapy in cocaine abusers. Journal of Substance Abuse Treatment. 2002;23:191–197
  14. Covi L, Lipman RS. Cognitive behavioral group psychotherapy combined with imipramine in major depression. Psychopharmacology Bulletin. 1987;23:173–176
  15. Crits-Christoph P, Siqueland L, McCalmont E, Weiss RD, Gastfriend DR, Frank A, et al. Impact of psychosocial treatments on associated problems of cocaine-dependent patients. Journal of Consulting and Clinical Psychology. 2001;69:825–830
  16. Delucchi KL, Jones RT, Batki SL. Measurement properties of quantitative urine benzoylecgonine in clinical trials research. Addiction. 1997;92:297–302
  17. Downey KK, Helmus TC, Schuster CR. Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Experimental and Clinical Psychopharmacology. 2000;8:176–184
  18. Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychology of Addictive Behaviors. 2003;17:73–82
  19. Etheridge RM, Craddock SG, Dunteman GH, Hubbard RL. Treatment services in two national studies of community-based drug abuse treatment programs. Journal of Substance Abuse. 1995;7:9–26
  20. FDA Talk PaperT02-38. Subutex and Suboxone approved to treat opiate dependence. 2002;(Retrieved 10-8-2002) http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.htmlAvailable:
  21. Fiorentine R. Counseling frequency and the effectiveness of outpatient drug treatment: revisiting the conclusion that "more is better". American Journal of Drug and Alcohol Abuse. 2001;27:617–631
  22. Fiorentine R, Hillhouse MP. Why extensive participation in treatment and twelve-step programs is associated with the cessation of addictive behaviors: an application of the addicted-self model of recovery. Journal of Addictive Diseases. 2003;22:35–55
  23. Gastfriend D. Buprenorphine treatment of cocaine abuse. Journal of Addictive Diseases. 1993;12:155–170
  24. Higgins ST, Alessi SM, Dantona RL. Voucher-based incentives. A substance abuse treatment innovation. Addictive Behaviors. 2002;27:887–910
  25. Higgins ST, Budney AJ, Bickel WK. Applying behavioral concepts and principles to the treatment of cocaine dependence. Drug and Alcohol Dependence. 1994;34:87–97
  26. Kosten T, Poling J, Oliveto A. Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction. 2003;98:665–671
  27. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sciences. 1989;44:887–892
  28. Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biological Psychiatry. 1989;26:637–639
  29. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003;98:7–22
  30. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavica. 2002;105:164–172
  31. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–1959
  32. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics. 2004;75:34–48
  33. Montoya ID, Hess JM, Preston KL, Gorelick DA. A model for pharmacological research-treatment of cocaine dependence. Journal of Substance Abuse Treatment. 1995;12:415–421
  34. Montoya ID, Svikis D, Marcus SC, Suarez A, Tanielian T, Pincus HA. Psychiatric care of patients with depression and comorbid substance use disorders. Journal of Clinical Psychiatry. 2000;61:698–705
  35. Oliveto A, Kosten T, Schottenfeld R, Ziedonis D. Cocaine abuse among methadone-maintained patients. [letter] American Journal of Psychiatry. 1993;150:1755
  36. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Archives of General Psychiatry. 2001;56:812–820
  37. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Archives of General Psychiatry. 1999;56:829–835
  38. Petry NM, Simcic F. Recent advances in the dissemination of contingency management techniques: clinical and research perspectives. Journal of Substance Abuse Treatment. 2002;23:81–86
  39. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry. 2000;57:395–404
  40. Public Law 106-310. (2000). 1. C. Drug Addiction Treatment Act.
  41. Rawson RA, Huber A, McCann M, Shoptaw S, Farabee D, Reiber C, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry. 2002;59:817–824
  42. Robles E, Silverman K, Preston KL, Cone EJ, Katz E, Bigelow GE, et al. The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug and Alcohol Dependence. 2000;58:205–212
  43. Rounsaville BJ, Gawin F, Kleber H. Interpersonal psychotherapy adapted for ambulatory cocaine abusers. American Journal of Drug and Alcohol Abuse. 1985;11:171–191
  44. Rounsaville BJ, Kleber HD. Psychotherapy/counseling for opiate addicts: strategies for use in different treatment settings. International Journal of the Addictions. 1985;20:869–896
  45. Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biological Psychiatry. 1993;34:66–74
  46. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry. 1997;54:713–720
  47. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Archives of General Psychiatry. 1996;53:409–415
  48. Siqueland L, Crits-Christoph P, Gallop R, Barber JP, Griffin ML, Thase ME, et al. Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. American Journal of the Addictions. 2002;11:24–40
  49. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl). 1994;116:401–406
  50. Tarrier N, Pilgrim H, Sommerfield C, Faragher B, Reynolds M, Graham E, et al. A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. Journal of Consulting and Clinical Psychology. 1999;67:13–18

PII: S0740-5472(05)00016-4

doi: 10.1016/j.jsat.2005.01.004

Journal of Substance Abuse Treatment
Volume 28, Issue 3 , Pages 247-254 , April 2005

Article Tools

* Image Usage & Resolution